Posted by Michael Wonder on 16 Dec 2024
FDA approves Vtama (tapinarof) cream, 1% for the treatment of atopic dermatitis in adults and children 2 years of age and older
16 December 2024 - In the pivotal studies, ADORING 1 and ADORING 2, up to 46% of patients on Vtama cream achieved vIGA-AD treatment success at Week 8 versus 18% of patients on vehicle.
Organon today announced that the US FDA has approved Vtama (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis in adults and paediatric patients 2 years of age and older.
